Rubicor Breast Biopsy Device §10(k) Notification
This summary of 510(k)-safety and effectiveness information is being submitted in
accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Date Prepared: December 21, 2001

510(k) number:_§ A OZOOY 7

Applicant Information: APR - 3 2002
Rubicor Medical, Inc.

849 Veterans Blvd.

Redwood City, CA 94063.

Contact Person: Ary Chernomorsky

Phone Number: (650) 556-1070

Fax Number: (650) 556-1821

Device Information:

Classification: Class I

Trade Name: Rubicor Breast Biopsy Device

Classification Name: Electrosurgical Device and accessories (21 CFR 870.4400)
Equivalent Device:

The subject device is substantially equivalent in intended use and/or method of operation to
the Neothermia En Bloc Biopsy System (K003190), the Ethicon Mammotome Hand-Held
System (K991980) and the USSC Autosuture Endo Catch (K922123).

Intended Use: . .

The Rubicor Breast Biopsy Device is intended for diagnostic sampling of breast tissue
during breast biopsy procedure.

The Rubicor Breast Biopsy Device is to be used for diagnostic purposes only and is not
intended for therapeutic uses.

Test Results:

Performance

Results of in-vitro testing demonstrate that the Breast Biopsy Device is safe and effective
for its intended use.

Biocompatibility

The materials used in the Rubicor Breast Biopsy Device meets the requirements of ISO
10993-1.

Summary: Based on the intended use, product, performance and biocompatability
information provided in this notification, the subject device has been shown to be
substantially equivalent to the currently marketed predicate devices.

Rubicor Medical, Inc. Page 18

get / : a
2 . DEPARTMENT OF HEALTH & HUMAN SERVICES - Public Health Service
we , : . . . : Food and: Drug Administration
: : co 9200 Corporate Boulevard oo
, : . , . Rockville MD 20850

Mr. Ary Cherriomorsky , —— ae
Vice President, Research and Development : :
Rubicor Medical, Inc. APR - 5 2002
849 Veterans Boulevard
Redwood City, CA 94063
Re: K020047

Trade/Device Name: Rubicor Breast Biopsy Device

Regulation Number: 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: II

Product Code: GEI

Dated: January 4, 2002

Received: January 7, 2002 :
Dear Mr. Chernomorsky:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The:
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (sce above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as sel
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

‘Page 2 — Mr. Ary Chernomorsky © , This letter will allow you to begin marketing your device as described in your Section 510(k)
/ premarket notification. The FDA finding of substantial equivalence of your device to a legally - ,
' marketed predicate device results in a classification for your device and thus, permits your device ,
‘ to proceed to the market. . . , ,
| If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and

additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of
Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of
your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the
regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97).
Other general information on your responsibilities under the Act may be obtained from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 443-6597 or at its Internet address
http:/Avww.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

(Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and
Radiological Health

Enclosure

a - Indications forUse  -—— a OO
oo 510(k) Number (if known): _ KoZoc Y-7 oe 7
Device Name: . _.  Rubicor Breast Biopsy Device . : a
Indications forUse: - .
The Rubicor Breast Biopsy Device is intended for diagnostic sampling of breast tissue
during breast biopsy procedure.
The Rubicor Breast Biopsy Device is to be used for diagnostic purposes only and
is not intended for therapeutic uses.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
a
Concurrence of CDRH, Office of Device Evaluation (ODE)
runam C Loved
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices
SS 510(k) Number 2004
Prescription Use OR Over-the Counter Use
(Per 21 CFR 801.109)
(Optional Format 1-2-96)

